Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo Strikes New Chinese JV As Beijing’s Reforms Gain Pace

Executive Summary

Aurobindo has formed a new joint venture with a Chinese partner to supply products for the world’s second-largest pharmaceutical market, as Beijing’s drug procurement reforms gather pace.

You may also be interested in...



Upbeat On Injectables, Aurobindo Is Hiking Capacities

Aurobindo expects revenues from injectables to increase to $650m-$700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets, though big-ticket M&A is ruled out.

Upbeat On Injectables, Aurobindo Hiking Capacities

Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.

Aurobindo Co-Founder Hit With $3m Fine For Insider Trading

Indian stock market regulator SEBI has slapped the billionaire founder of Aurobindo Pharma, along with other promoters of the company, with a more than $3m fine for allegedly violating insider trading norms over a string of licensing agreements with multinational Pfizer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel